Following a slump sale of its hospital business to MGM Healthcare during FY24, the company has ceased all business operations and now records no revenue from operations. Management and the Board are evaluating corporate restructuring options with no visibility of commencing new operations. Statutory auditors B S R & Co. LLP issued an unmodified opinion but added an Emphasis of Matter regarding going concern. The company holds approximately Rs 3,458.24 lakh in cash and bank balances. Contingent liabilities include medico-legal claims of about Rs 649.40 lakh and VAT-related demands of about Rs 254.93 lakh. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Other income and interest. Cash shell — no active business after slump sale of hospital operations
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 86 | 86 | 59 | 0 | 0 |
| EBITDA (ex other income) | 8 | 5 | 57 | (2) | (2) |
| margin % | 8.9 | 5.3 | 96.1 | — | (3083.8) |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | (4.41) | (8.26) | 24.18 | 0.21 | 2.21 |
| ROE % · ROCE % | (10.3) · (1.3) | (24.1) · (0.9) | 41.4 · 49.6 | 1.3 · 1.9 | 12.0 · 13.8 |
| Debt / equity (x) | 0.67 | 0.72 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 7 | 6 | (7) | 2 | 1 |
| Capex | (1) | 0 | (2) | 0 | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Net profit | (0) | 0 | 0 | 0 | 4 | 0 | 0 | (0) |
| EPS (₹) | (0.03) | 0.05 | 0.00 | 0.19 | 2.22 | 0.01 | 0.01 | 0.02 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) | 14.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Aug 2026 · Q1 FY27 results published in newspapers under SEBI rule | compliance | minimal | — | — |
| 4 Aug 2026 · Fortis Malar Q1 FY27 Results: No Business Ops, Evaluating Restructuring | results | medium | — | — |
| 4 Aug 2026 · Q1FY27 results: company has no active business after slump sale | results | high | — | — |
| 29 Jul 2026 · 35th AGM voting results: All 3 resolutions passed with over 99.98% approval | compliance | minimal | — | — |
| 29 Jul 2026 · Fortis Malar Hospitals 35th AGM held via video conferencing on July 29, 2026 | board shareholder meetings | medium | — | — |
| 29 Jul 2026 · 35th AGM proceedings of Fortis Malar Hospitals held on July 29, 2026 | board shareholder meetings | medium | — | — |
| 28 Jul 2026 · Fortis Malar board to consider Q1 FY27 results on August 4 | results | low | — | — |
| 9 Jul 2026 · Routine quarterly compliance filing under SEBI Regulation 74(5) | compliance | minimal | — | — |
| 3 Jul 2026 · Notice for 35th AGM on July 29 2026 via video conferencing published in newspapers | compliance | minimal | — | — |
| 2 Jul 2026 · AGM notice and FY26 annual report weblink shared with shareholders | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.5 | 47.3 | 9 of 30 | 72% |
| P/B | 2.4 | 6.2 | 4 of 24 | 87% |
| ROCE | 13.8 | 10.9 | 9 of 30 | 72% |
| ROE | 12.1 | 11.8 | 12 of 24 | 52% |
| Debt / Equity | 0.0 | 0.2 | 1 of 24 | 91% |
| EBITDA margin | 3451.6 | 22.0 | 1 of 24 | 100% |
| Profit growth | (112.5) | 8.1 | 21 of 21 | 0% |
| Market cap | 83 | 2415 | 26 of 30 | 14% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
